(Q35023612)

5 August 2017

1 reference

title

Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets (English)

1 reference

5 August 2017

1 reference

1 reference

1 reference

3

Steven Haffner

1 reference

5 August 2017

Jorge Plutzky

1

1 reference

5 August 2017

Giancarlo Viberti

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Journal of Diabetes and its Complications

5 August 2017

published in

1 reference

5 August 2017

volume

16

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

401-415

1 reference

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Nuclear Factor- B Suppressive and Inhibitor- B Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Microalbuminuria in patients with NIDDM: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Microalbuminuria: what is it? Why is it important? What should be done about it?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Novel clinical markers of vascular wall inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Glucose scavenging of nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

PPAR agonists as direct modulators of the vessel wall in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Metformin increases circulating tumour necrosis factor-alpha levels in non-obese non-diabetic patients with coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Induction of T-cell activation by oxidized low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Inhibition of vascular smooth muscle cell migration by intact endothelium is nitric oxide-mediated: interference by oxidised low density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Cardiovascular risk continuum: implications of insulin resistance and diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Diabetes mellitus and diabetes-associated vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effects of current therapeutic interventions on insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Endothelial dysfunction in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

CD40 signaling in vascular cells: a key role in atherosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Improved endothelial function with metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Microalbuminuria and coronary heart disease in NIDDM: an incidence study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The gene expression profile of human umbilical vein endothelial cells stimulated by tumor necrosis factor alpha using DNA microarray analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone directly increases HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Reactive oxygen species in essential hypertension and non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Atherosclerotic plaque rupture: emerging insights and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Low-density lipoprotein particle size, triglyceride-rich lipoproteins, and glucose tolerance in non-diabetic men with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Improvement of glycemic control by 1 year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Postprandial triglycerides and blood coagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Role of adhesion molecules in vascular regulation and damage

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Modulation of soluble phases of endothelial/leukocyte adhesion molecule 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 with interleukin-1beta after experimental endotoxic challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Platelet dysfunction in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Troglitazone improves endothelial dysfunction in patients with insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

The role of plaque rupture and thrombosis in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

Peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2802%2900202-7

7 January 2021

10.1016/S1056-8727(02)00202-7

Identifiers

DOI

1 reference

5 August 2017

1 reference